We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine
View Top Employees from Satsuma Pharmaceuticals, Inc.Website | http://www.satsumarx.com |
Ticker | STSA |
Revenue | $7.1 million |
Employees | 27 (27 on RocketReach) |
Founded | 2016 |
Address | 395 Oyster Point Boulevard Suite 300, South San Francisco, California 94080, US |
Phone | (650) 410-3200 |
Technologies |
JavaScript,
HTML,
PHP
+24 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Pharmaceutical, Health Care, Therapeutics |
Web Rank | 18 Million |
Keywords | Satsuma Ipo, Satsuma Pharmaceuticals, Inc., Albrecht, Detlef, Satsuma Pharmaceuticals |
Competitors | Aequus Pharmaceuticals, Annexon Biosciences, Applied Therapeutics Inc, CellCentric, Lisata Therapeutics, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Satsuma Pharmaceuticals, Inc. employee's phone or email?
The Satsuma Pharmaceuticals, Inc. annual revenue was $7.1 million in 2024.
Shannon Strom is the Vice President and Head of Regulatory Affairs of Satsuma Pharmaceuticals, Inc..
27 people are employed at Satsuma Pharmaceuticals, Inc..
Satsuma Pharmaceuticals, Inc. is based in South San Francisco, California.
The NAICS codes for Satsuma Pharmaceuticals, Inc. are [32, 3254, 541, 54, 325, 32541].
The SIC codes for Satsuma Pharmaceuticals, Inc. are [28, 283].